IMS: 2014 hospital medication statistics report

Source: according to the statistics of the overall market performance of China medical elite club on September 19, 2014, the sales volume (purchase amount of hospital pharmacy) of China's hospital medical market in the first quarter of 2014 was 144.04 billion yuan (data source: IMS Ames China Hospital Pharmaceutical statistical report ≥ 100 beds), with a sales growth rate of 12.9% compared with the same period last year The growth rate is about 2% lower than that of last quarter Based on the 12-month mat (rolling annual data: the sum of data traced back 12 months from the specified time node, which refers to the sales volume from the second quarter of 2013 to the first quarter of 2014 ）In the first quarter of 2014, the mat growth rate was 13.8%, basically the same as the previous quarter The main reason for the continuous slowdown in growth is still the impact of government anti drug restrictions, especially for the products of local enterprises After the five rounds of drug price reduction since 2011, the total amount control of large hospitals in major cities has increased, and the drug prescriptions have tended to be conservative, especially in the use of antibiotics and medical solutions, which are undoubtedly the reasons for the slowdown in market growth The market performance of multinational enterprises and domestic enterprises in the first quarter of 2014 saw a growth rate of 12.5% for local enterprises, a decrease of nearly 3 percentage points compared with the previous quarter, but it was basically the same as the 12.1% in the first quarter of 2013 Multinational enterprises rose 14.2%, the first time in recent years that their growth rate exceeded that of local enterprises In terms of rolling annual data, domestic enterprises are still leading In the first quarter of 2014, Pfizer maintained its leading position in Chinese hospital medicine market with sales volume of 3.66 billion yuan and growth rate of 18.2% AstraZeneca ranked second with a sales volume of 2.99 billion yuan, and Qilu pharmaceutical ranked third with a sales volume of 2.462 billion yuan, which continues the best ranking of Chinese local enterprises According to the rolling annual data, Novartis (25.7%), Qilu (19.8%) and AstraZeneca (18.7%) are the fastest growing companies In six provinces of Shandong, Henan, Jiangsu, Zhejiang, Guangdong and Sichuan, which can cover 40% of the hospital channel sales in China, multinational enterprises have outstanding performance in Guangdong and Zhejiang, all of which can reach more than 30% market share Among the four cities, the growth rate of tier one cities is the lowest, while tier one and tier two cities are the key areas of multinational enterprises, while the market growth of tier three and tier four cities is mostly contributed by local enterprises In the first quarter of 2014, the sales volume was RMB 27.92 billion, with a growth rate of 12.9% The growth of systemic anti infective products is also stabilizing, reaching 10.6%, continuing the growth trend in the fourth quarter of 2013 From the perspective of products, in the first quarter of 2014, there were 7 products of local enterprises and 3 products of multinational enterprises in the top 10 products list Among the top three products, the products of local enterprises accounted for 2 seats, respectively, Xueshuantong, which ranked first in the list of hospital drugs with a quarterly sales volume of 86.3 million yuan; Shenjie rose to the second with a quarterly sales volume of 84.1 million yuan Third place was Sanofi's plavius.